From blood collection to reinfusion, the life-saving time window is shortened.

Based on the research published by the team of Carl June from the University of Pennsylvania and BioFactory company on March 8, 2025, in "Nature Biotechnology" (Original Title: Scalable Closed-System Manufacturing of CAR-T Cells Enables Rapid, Cost-Effective Production).

"Father of CAR-T, Carl June, is a co-corresponding author. This automated platform transitions CAR-T therapy from 'handcrafted' to the 'industrial era,' reducing patient wait times from weeks to 48 hours. This is a crucial leap towards making life-saving therapy accessible to all." - Professor Carl June。”

In March 2025, Carl June's team unveiled the world's first fully automated closed CAR-T cell production line in "Nature Biotechnology," marking a significant step in the industrialization of cell therapy. This cutting-edge technology, combining robotic clusters and intelligent bioreactors, addresses the challenges of traditional CAR-T production, such as manual processes, lengthy cycles, and high costs.

Traditional CAR-T therapy involves manual handling of patient cells in clean rooms, taking 2-3 weeks with a high failure rate. The new platform features:

• An "unmanned" assembly line: Robotic arms handle processes from blood sample separation to cell amplification in a closed chamber, reducing contamination risks.

• Intelligent monitoring: Embedded sensors analyze cell viability and optimize cultivation parameters in real-time using AI.

• Modular amplification: Stackable bioreactors meet dosage requirements from children to adults in a single batch.

Clinical trials have shown:

✅ 40% lower production costs compared to traditional methods

✅ Production cycles shortened to 3-5 days (as fast as 48 hours)

✅ Improved cell activity and treatment outcomes compared to manual production

This advancement in automated cell production signifies a shift towards more efficient and cost-effective cell therapy manufacturing, promising enhanced accessibility and treatment effectiveness.

The rise of automated cell production relies on precise and reliable consumables to support large-scale cell amplification. Each cell respiration during the process requires an extremely stable environment.

Basel plays a fundamental role in driving the industrialization of cell therapy. Our cell factory system, designed with high-quality medical materials and meeting GMP standards, ensures zero leakage and contamination during large-scale cell cultivation, serving as a trusted "cell amplification cornerstone" in automated production lines.

Authoritative Source Link:

• Research Summary：https://www.nature.com
• Penn News Release：https://penntoday.upenn.edu/news/car-t-manufacturing-breakthrough